🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

Neurocrine Biosciences, Inc. NBIX R3KPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · United States
https://www.neurocrine.com
Company Profile ↓
$155.13
+17.86% 1Y
Mkt Cap$15.77B
P/E22.65
P/B4.02
52W High$185.50
52W Low$123.10
Book Value$36.35
EPS (TTM)$6.85

Company Overview

Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 22.1%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 15.9%.

Steady Revenue Expansion

Revenue has grown at a 53.7% CAGR over the past five years.

Reasonable Valuation

Trades at a P/E of 22.6, below the sector median of 24.8.

Healthy Margins

Maintains a net profit margin of 20.9%.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.12.

Recent Developments

  • Dec 2025 Revenue of $2.86B (+21.4% YoY); net profit $478.60M.
  • Trailing 12 Months Year-on-year growth — revenue +39.5%, earnings +31.1%.
  • 5-Year Trend Long-term compounding — revenue CAGR 53.7%, profit CAGR 3.3%.

Growth & Price Performance

Compounded Sales Growth

5 Years:53.69%
1 Year:39.50%

Compounded Profit Growth

5 Years:3.28%
1 Year:31.10%

Stock Price Performance

1 Year:+17.86%
6 Months:+19.40%
3 Months:-4.90%
1 Month:-5.07%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed
52-Week Range 51% of range
$123.10 $185.50
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMAAbove
  • RSI (14)43.23 · Neutral
Price Performance
1M-5.07%
3M-4.90%
6M+19.40%
1Y+17.86%
Valuation vs Sector

P/E of 22.65 is below the sector median of 24.83 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Strong return on equity of 22.1%.
  • Excellent profit margin of 20.9%.
  • Compounding revenue at 53.7% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
22.65
Industry PE
24.83
Forward P/E
12.96
PEG Ratio
0.30
Book Value
$36.35
Price to Book
4.02
P/S
4.41
EV/EBITDA
16.35
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
53.69%
Profit 5Y
3.28%
Revenue (YoY)
39.50%
Earnings (YoY)
31.10%

Profitability & Returns

ROCE
15.92%
ROE
22.09%
ROA
11.70%
Profit Margin
20.91%
Op Margin
22.19%
Gross Margin
64.48%
EPS (Latest Qtr)
$1.39
EPS (TTM)
$6.85

Balance Sheet & Liquidity

Debt/Equity
0.12
Quick Ratio
1.46
Current Ratio
1.87
Debt
$461.60M
Total Assets
$5.36B
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
1.06%
Chg in Prom Hold
-0.00%
FII / Inst Holding
102.68%
Chg in FII Hold
-0.16%

Financial Snapshot

Enterprise Value
$15.77B
Total Revenue (TTM)
$3.37B
EBITDA
$913.30M
Free Cash Flow
$638.24M
Operating Cash Flow
$898.10M
Shares Outstanding
101.65M
Gross Margin
64.48%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 NBIX Neurocrine Biosciences, Inc. R3KPHARMA 155.13 22.65 $15.77B 0.00% 15.92% 22.09% 53.69% 3.28%
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,123.91 37.80 $1.00T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 269.12 31.22 $648.55B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 248.78 70.48 $439.62B 2.78% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 148.46 118.77 $366.28B 2.31% - 6.96% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 400.84 25.74 $359.79B 2.47% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 137.70 20.80 $261.73B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 160.04 23.99 $248.20B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 603.02 32.49 $222.97B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Jun 2015Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Mar 2026Jun 2026
Revenue -------06.33M60.77M94.52M71.09M96.91M151.76M131.49M138.40M183.50M222.10M244.10M237.10M302.40M258.50M247.90M236.60M288.90M296.00M310.60M378.20M387.90M420.40M452.70M498.80M515.30M590.20M622.10M572.60M687.50M794.90M814.50M959.00M
Operating Income -25.32M-35.84M--20.86M-41.83M-38.44M--79.93M-57.27M-6.00M--37.45M-1.85M54.32M--101.00M34.40M90.10M-58.90M76.60M-44.30M-31.50M62.80M44.50M3.10M54.70M87.80M-114.20M73.60M141.20M99.30M145.40M183.80M23.60M145.60M239.00M193.40M151.50M
Net Income -23.99M-34.44M-29.32M-19.26M-40.28M-36.89M-44.66M-78.33M-59.98M-11.12M6.89M-41.82M-5.91M50.76M18.08M-102.10M51.30M53.80M34.00M37.40M79.60M-57.60M347.90M32.10M42.30M22.50M13.90M-16.90M68.50M-76.60M95.50M83.10M43.40M65.00M129.80M7.90M107.50M209.50M197.90M144.40M
Diluted EPS --------0.90-0.68-0.130.07-0.47-0.070.520.19-1.120.540.560.350.390.81-0.623.580.330.430.230.14-0.180.69-0.790.950.820.420.631.240.081.062.041.911.39
R&D Expense 18.72M24.39M-23.90M26.86M20.94M-51.88M21.87M22.46M-48.95M36.99M35.48M-37.65M61.69M--58.30M---73.20M----------------

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 2.95M33.50M77.41M53.14M2.92M019.77M15.00M161.63M451.20M788.10M1.05B1.13B1.49B1.89B2.36B2.86B
Operating Income -53.67M-13.72M33.92M1.45M-49.68M-64.41M-94.20M-147.37M-131.36M36.80M72.30M163.00M102.50M249.00M250.90M570.50M619.10M
Net Income -51.04M-7.97M37.57M5.03M-46.09M-60.54M-88.93M-141.09M-142.54M21.10M37.00M407.30M89.60M154.50M249.70M341.30M478.60M
Diluted EPS -1.30-0.150.670.08-0.69-0.81-1.05-1.63-1.620.220.394.160.921.562.473.294.67
R&D Expense 33.72M31.15M30.95M37.16M39.25M46.42M81.49M94.29M121.83M160.52M-------

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --144.42M138.37M195.98M154.68M243.03M474.79M365.09M817.59M993.15M1.31B1.73B2.07B2.37B3.25B3.72B4.63B
Total Equity 36.77M3.95M19.34M60.08M154.37M120.41M208.70M424.45M314.88M372.20M480.80M636.90M1.13B1.37B1.71B2.23B2.59B3.25B
Cash & Equivalents 68.47M37.33M54.05M50.11M63.75M44.79M31.01M74.19M83.27M254.71M141.71M112.30M187.10M340.80M262.90M251.10M233.00M713.00M
Total Liabilities --125.08M78.29M41.61M34.27M34.33M50.33M50.21M445.45M512.39M669.10M608.50M698.50M660.90M1.02B1.13B1.38B
Current Liabilities --52.78M47.11M15.65M11.70M15.66M25.71M30.41M54.43M88.23M565.30M186.50M245.80M537.70M654.80M507.70M743.40M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -53.09M49.94M-698.00K-35.29M-29.61M---106.18M-94.33M101.40M147.00M228.50M256.50M339.40M389.90M595.40M782.70M
Investing Cash Flow 12.06M-54.70M-3.53M-34.76M5.34M--112.95M-251.25M-242.90M-211.10M4.10M-130.20M-177.10M-467.10M-126.80M-264.40M
Financing Cash Flow 9.90M21.48M286.00K83.70M5.30M--2.39M516.65M29.50M32.40M-157.80M27.40M-234.30M65.30M-486.70M-38.30M
Capital Expenditure -35.00K-315.00K-750.00K-971.00K-545.00K-1.61M-1.93M-4.11M-6.94M-24.80M-14.70M-10.90M-23.40M-16.50M-28.30M-38.20M-34.00M
Free Cash Flow -53.13M49.63M-1.45M-36.27M-30.15M---110.29M-101.27M76.60M132.30M217.60M233.10M322.90M361.60M557.20M748.70M
Share Buybacks -------------00300.00M167.70M

Ratios (Annual)

Figures in %.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -----------------
Operating Margin % -1,817.5%-41.0%43.8%2.7%-1,701.9%--476.5%-982.5%-81.3%8.2%9.2%15.6%9.0%16.7%13.3%24.2%21.6%
Net Margin % -1,728.3%-23.8%48.5%9.5%-1,579.0%--449.8%-940.6%-88.2%4.7%4.7%38.9%7.9%10.4%13.2%14.5%16.7%
ROE % -1,290.8%-41.2%62.5%3.3%-38.3%-29.0%-21.0%-44.8%-38.3%4.4%5.8%36.2%6.5%9.0%11.2%13.2%14.7%
ROCE % --15.0%37.2%0.8%-34.7%-28.3%-21.0%-44.0%-17.2%4.1%9.8%10.5%5.6%13.6%9.7%17.8%15.9%

Shareholding Pattern

Insiders
1.06%
Institutions
102.68%
Public Float
103.78%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 13.49% 13.71M $2.01B
2 JPMORGAN CHASE & CO 6.29% 6.40M $935.68M
3 Dodge & Cox Inc. 5.49% 5.58M $816.65M
4 Vanguard Portfolio Management LLC 4.89% 4.97M $727.36M
5 Vanguard Capital Management LLC 4.47% 4.55M $664.66M
6 State Street Corporation 4.31% 4.39M $641.31M
7 AQR Capital Management, LLC 3.76% 3.82M $558.31M
8 Renaissance Technologies, LLC 2.30% 2.34M $341.58M
9 Geode Capital Management, LLC 2.10% 2.14M $312.75M
10 Two Sigma Investments, LP 2.04% 2.08M $303.61M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for NBIX

Google News Sat, 05 Sep 2026

NEUROCRINE BIOSCIENCES INC (NBIX) Stock Chart - ChartMill

<a href="https://news.google.com/rss/articles/CBMiZEFVX3lxTFB4TWdGYmo5N01lVF9hc2tfcXFpWkNQZjExcXpxNGZyT0JJeHpEbF9GYnVIbjY0SmVsOVptSWNxSFduMHJJQy1CRzVfcFVrRE0wYW1zLXdPcWNlR1QxeWVSS0g2dEQ?oc=5" target="_blank">NEUROCRINE BIOSCIENCES INC (NBIX…

Google News Sun, 06 Sep 2026

Neurocrine Biosciences (NBIX) Stock Could Still Be A Bargain After A 61% Run - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi7AFBVV95cUxOdE1OUG9nNlRIMG94S081MmoxTmtxeHFHeEZDczQ5RmxCbXpBcjFRRjgydnhMbTE4VDZTaFVLb3d1UTMzZk5HZVVoRllRZWxzeVBlMFZLVHliQ1V1NElnbDNiSmsweUd6d2RfanhFN1JsVjBaNGtCQzFwRE0wanhFaGdKWVRZWExOd01zSU…

Google News Mon, 07 Sep 2026

Neurocrine Biosciences, Inc. (NBIX) Stock Analysis: Exploring a 36% Upside Potential with Robust Revenue Growth - directorstalkinterviews.com

<a href="https://news.google.com/rss/articles/CBMi7AFBVV95cUxPZ3RETjhudnF0QlgxcmN3ZGRBWklxeUpnU3dab2tZSVFwTXlZQzFNc2ZPbTJES3MxSjNnTkpfTC1UNmh0Z0g2aXdLVGZtRXdQY05lRGNyQnFFUjRJYzFIR1hlaWZlM0NmQWRXajMtNWxvR3I0Z0lMMmtYMFRUZ3dZZ21iR185blN2U3Vva0…

Google News hu, 20 Aug 2026

Is NBIX Stock a Buy as Fast Growth Meets a Premium Sales Valuation? - finance.yahoo.com

<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxQRUpEV1gzRnFadnIyOHdwRm9LZDhqVG9nSFg1ZnJ2dFZmMkxzUWhybEVnTk5BZVJyWEg2Rko3SzdNMjFoaWlBRmNncVZxT3JVWlJ0SnpjaU1iY19qNmJJcEpzUFd2NkpLQWRHX3Q2dHlKS19Ya3dfbUxRUmlSZkhaVzhVN3E0a09DRjlRaU…

Google News Fri, 04 Sep 2026

Neurocrine (NBIX) director donates 1,000 shares - Stock Titan

<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxOVzFxbFRWMlFJQWMyU1dncUNMY2s3Y1hNc1F5OWlXWmhCbWlkbjBqUXR6d0JMdjhZR3c1cFJpTkRWZlRzWFpTNzc2SHNCS0pKS2J6RGlOUThsUFBjODAxTVBFQnk1YVNsRnNMQlhnQ0l2Yms1Z0VjLVg3MVJUeXV3cWt0LU1wWnNCanZwOG…

Google News Mon, 24 Aug 2026

Neurocrine Biosciences (NBIX) Stock Still Looks Like A Bargain Following Its 59% Run - Sahm

<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxOdXRVWUZiRUZKVGJnWWYyZTVXSEphelpxa05GNjJmVlZsR012c0ZrOTBlcGprdUFlTk1zaF9RM2d6aHUwX203VHJpU1hjZlF6cXR6bzlBSXdYR2U2dHl2MFBpREdRR1RYN1pPbVRWTjlodnU1RmNkQlU5cllsOWlISTVlaFpMalVZNzVHNz…

NBIX — Frequently Asked Questions

What is the current share price of Neurocrine Biosciences, Inc. (NBIX)?

As of 2026-09-19 21:16 PDT, Neurocrine Biosciences, Inc. (NBIX) trades at $155.13 on NasdaqGS. Its 52-week range is $123.10 to $185.50.

What is the market capitalisation of NBIX?

Neurocrine Biosciences, Inc. (NBIX) has a market capitalisation of $15.77B on NasdaqGS.

What is the P/E ratio of NBIX?

NBIX trades at a trailing price-to-earnings (P/E) ratio of 22.65. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 4.02.

What is the return on equity (ROE) of NBIX?

NBIX has a return on equity (ROE) of 22.09%. Its return on capital employed (ROCE) is 15.92%.

Is NBIX a good stock to buy?

This page provides a data-driven analysis of Neurocrine Biosciences, Inc. (NBIX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space